D&A Pharma

D&A Pharma is a private, European biopharmaceutical company specializing in repurposing and reformulating known drugs for addiction treatment, particularly Alcohol Use Disorders (AUD). Its lead asset, Hopveus®, is a patented solid formulation of sodium oxybate (SMO) designed as an abuse-deterrent outpatient treatment for AUD, which recently had a key EU marketing authorization rejection overturned by the Court of Justice. The company operates with an integrated model covering R&D through commercialization across Europe, targeting niche therapeutic areas often overlooked by larger pharmaceutical firms.

Reformulation and repurposing platform for known active ingredients, specializing in creating abuse-deterrent, solid oral formulations to improve safety, compliance, and efficacy.

The competitive landscape for AUD treatments is relatively sparse, with few approved pharmacological options, providing an opening for Hopveus®. However, it will compete against existing therapies (like nalmefene, acamprosate, disulfiram) and must differentiate based on its abuse-deterrent formulation and the established safety profile of its active ingredient. In narcolepsy, the competition is more crowded with several approved oxybate and non-oxybate treatments.